SCHEMBL7469798

SCHEMBL7469798

Cc1cccc(COc2cccc(OCc3ccc4cc(F)cc(F)c4n3)c2)c1[O]

nearest known ligand 0.40

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
CYSLTR1 Q9Y271 11/20 0.40
CYSLTR2 Q9NS75 7/20 0.40
GPBAR1 Q8TDU6 6/20 0.39
PDE10A Q9Y233 1/20 0.36
CCNB2 O95067 1/20 0.36
CDK1 P06493 1/20 0.36
CDK4 P11802 1/20 0.36
CCNB1 P14635 1/20 0.36
CCND1 P24385 1/20 0.36
CCNB3 Q8WWL7 1/20 0.36
NOS3 P29474 1/20 0.35
NOS1 P29475 1/20 0.35
NOS2 P35228 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7469808 0.87 CYSLTR1 (0.40) CYSLTR1CYSLTR2GPBAR1PDE10A
SCHEMBL6090077 0.83 CYSLTR1 (0.42) CYSLTR1CYSLTR2GPBAR1
SCHEMBL6088342 0.82 CYSLTR1 (0.35) CYSLTR1CYSLTR2GPBAR1PDE10A
SCHEMBL7458445 0.80 CYSLTR1 (0.62) CYSLTR1CYSLTR2GPBAR1PDE10A
SCHEMBL5725667 0.75 CYSLTR1 (0.46) CYSLTR1CYSLTR2GPBAR1PDE10ACCNB2
SCHEMBL7460389 0.73 CYSLTR1 (0.50) CYSLTR1CYSLTR2GPBAR1PDE10A
SCHEMBL6088777 0.72 CYSLTR1 (0.55) CYSLTR1CYSLTR2GPBAR1
SCHEMBL6089165 0.70 CYSLTR1 (0.54) CYSLTR1CYSLTR2
SCHEMBL6087773 0.69 CYSLTR1 (0.52) CYSLTR1CYSLTR2GPBAR1
SCHEMBL6091468 0.68 CYSLTR1 (0.51) CYSLTR1CYSLTR2GPBAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1177176-A1 TRI-ARYL ACID DERIVATIVES AS PPAR RECEPTOR LIGANDS Aventis Pharma Deutschland GmbH (DE) 2002-02-06 EP disclosed
WO-2000064876-A1 TRI-ARYL ACID DERIVATIVES AS PPAR RECEPTOR LIGANDS AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2000-11-02 WO disclosed